Deltex Medical Group Plc (LON:DEMG) CEO Ewan Phillips talks to DirectorsTalk about today’s results. Ewan talks us through the highlights, initiatives for the UK market, the 3 new platform accounts
Deltex Medical Group plc (AIM: DEMG), the global leader in oesophageal Doppler monitoring (“ODM”), has told DirectorsTalk that it has added two additional accounts to its platform programme in the
Deltex Medical Group plc (LON:DEMG) CEO Ewan Phillips talks to DirectorsTalk about the release of the initial results from the largest ever randomised clinical trial of ODM which showed substantial
Ewan Phillips, Deltex Medical’s Chief Executive, commented: “These are superb results from the largest ever ODM randomised controlled trial. They confirm the unique ability of ODM to help doctors eliminate more
Deltex Medical Group’s Ewan Phillips discusses the launch of TruFlow, the improvements for physicians, encouraging sales and reducing the number of dedicated trainers in this exclusive interview with DirectorsTalk
Deltex Medical Group Plc (LON:DEMG) Chief Executive Ewan Philips talks to DirectorsTalk about the launch of TruFlow the new, wider beam, single patient disposable probe, it’s improvements encouraging sales and
Deltex Medical Group plc (AIM: DEMG), the global leader in oesophageal Doppler monitoring (ODM), today told DirectorsTalk about the launch of TruFlow, a the new, wider beam, single patient disposable
Deltex Medical Group’s Ewan Phillips discusses their results for year-ending 31st December 2015 in this exclusive interview with DirectorsTalk
Deltex Medical Group Plc (LON:DEMG) CEO Ewan Phillips talks to DirectorsTalk about an impressive results summary for 2015. Ewan talks through the key highlights, how the US is developing as
Nigel Keen, Chairman of Deltex Medical LON:DEMG commented: “Deltex made significant progress in 2015 despite continuing difficulties in the UK. Total export sales were approximately 20% ahead with over 40% growth in the
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
